Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2017 2
2018 1
2019 1
2021 1
2022 1
2023 3
2024 2
2025 5
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20RW, 5BAuthor
Page 1
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Moehler M, et al. J Clin Oncol. 2023 Dec 10;41(35):5388-5399. doi: 10.1200/JCO.23.00170. Epub 2023 Sep 15. J Clin Oncol. 2023. PMID: 37713657 Free PMC article. Clinical Trial.
METHODS: In patients (N = 1,581) concurrently randomly assigned 1:1 to nivolumab plus chemotherapy or chemotherapy and in those with tumor PD-L1 expression at a combined positive score (CPS) of 5, health-related quality of life (HRQoL) was assessed using the EQ-5D and Fun …
METHODS: In patients (N = 1,581) concurrently randomly assigned 1:1 to nivolumab plus chemotherapy or chemotherapy and in those with tumor P …
MeDeMSA care study protocol: developing personalized best medical care with integrated mobile palliative and telemedicine support for individuals with multiple system atrophy.
Fanciulli A, Caliò B, Schmidt S, Goebel G, Leys F, Radl K, Breitegger C, Arvandi M, Blum A, Gabl C, Galvan O, Herms A, Högl B, Holzner B, Jagusch F, Kiechl S, Knoflach-Gabis A, Koegl M, Kuchin I, Lorenzl S, Poewe W, Prajczer S, Rumpold G, Schlager A, Schrag A, Seppi K, Siebert U, Schönherr G, Sroczynski G, Schmidhuber M, Schwingenschuh P, Jahn B, Krismer F, Wenning GK. Fanciulli A, et al. J Neural Transm (Vienna). 2025 May 24. doi: 10.1007/s00702-025-02933-z. Online ahead of print. J Neural Transm (Vienna). 2025. PMID: 40411588
This 18-month, monocentric, open-label study evaluates the impact of a personalized, multidisciplinary treatment, integrating mobile palliative care, on the quality of life (QoL, measured by EQ-5D-5L indices) of MSA individuals compared to a matched historical European MSA …
This 18-month, monocentric, open-label study evaluates the impact of a personalized, multidisciplinary treatment, integrating mobile palliat …
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Cella D, Motzer RJ, Suarez C, Blum SI, Ejzykowicz F, Hamilton M, Wallace JF, Simsek B, Zhang J, Ivanescu C, Apolo AB, Choueiri TK. Cella D, et al. Lancet Oncol. 2022 Feb;23(2):292-303. doi: 10.1016/S1470-2045(21)00693-8. Epub 2022 Jan 12. Lancet Oncol. 2022. PMID: 35032437 Free PMC article. Clinical Trial.
Disease-related symptoms were evaluated using the 19-item Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19), and global health status was assessed with the three-level EQ-5D (EQ-5D-3L) visual analogue scale (VAS) and UK utility index. PRO analys …
Disease-related symptoms were evaluated using the 19-item Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19), and global …
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Cheng Y, Sakai H, Paz-Ares L, Lu S, John T, Sun X, Moisei A, Taylor F, Lawrance R, Zhang X, Sylvester J, Yuan Y, Blum SI, Penrod JR, Carbone DP. Reck M, et al. Eur J Cancer. 2023 Apr;183:174-187. doi: 10.1016/j.ejca.2023.01.015. Epub 2023 Jan 28. Eur J Cancer. 2023. PMID: 36871487 Free article.
METHODS: In patients (N = 719) randomised 1:1 to nivolumab plus ipilimumab with chemotherapy or chemotherapy alone, disease-related symptom burden and health-related quality of life were assessed using the Lung Cancer Symptom Scale (LCSS) and 3-level EQ-5D (EQ-5D-3L …
METHODS: In patients (N = 719) randomised 1:1 to nivolumab plus ipilimumab with chemotherapy or chemotherapy alone, disease-related symptom …
Real-World Cost-Effectiveness of Pulmonary Vein Isolation for Atrial Fibrillation: A Target Trial Approach.
Serra-Burriel M, Aebersold H, Foster-Witassek F, Coslovsky M, Rodondi N, Blum MR, Sticherling C, Moschovitis G, Beer JH, Reichlin T, Krisai P, Aeschbacher S, Paladini RE, Kühne M, Osswald S, Conen D, Felder S, Schwenkglenks M; Swiss-AF investigators. Serra-Burriel M, et al. Value Health. 2023 Dec;26(12):1721-1729. doi: 10.1016/j.jval.2023.08.008. Epub 2023 Sep 22. Value Health. 2023. PMID: 37741443 Free article.
Resource utilization and cost information were collected through claims data. Quality of life was measured with EQ-5D-3L utilities. We estimated incremental cost-effectiveness ratios (ICERs) from the perspective of the Swiss statutory health insurance system. ...
Resource utilization and cost information were collected through claims data. Quality of life was measured with EQ-5D-3L utilities. W …
Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort.
Aebersold H, Foster-Witassek F, Aeschbacher S, Beer JH, Blozik E, Blum M, Bonati L, Conte G, Coslovsky M, De Perna ML, Di Valentino M, Felder S, Huber CA, Moschovitis G, Mueller A, Paladini RE, Reichlin T, Rodondi N, Stauber A, Sticherling C, Szucs TD, Conen D, Kuhne M, Osswald S, Schwenkglenks M, Serra-Burriel M; Swiss-AF Investigators. Aebersold H, et al. Open Heart. 2024 Jan 31;11(1):e002567. doi: 10.1136/openhrt-2023-002567. Open Heart. 2024. PMID: 38302139 Free PMC article.
Clinical data, healthcare resource utilisation and EQ-5D-based utilities representing quality of life were collected in yearly follow-ups. ...
Clinical data, healthcare resource utilisation and EQ-5D-based utilities representing quality of life were collected in yearly follow …
A Kolmogorov metric embedding for live cell microscopy signaling patterns.
Aho L, Winter M, DeCarlo M, Frismantiene A, Blum Y, Gagliardi PA, Pertz O, Cohen AR. Aho L, et al. Bioinform Adv. 2025 Mar 22;5(1):vbaf063. doi: 10.1093/bioadv/vbaf063. eCollection 2025. Bioinform Adv. 2025. PMID: 41064112 Free PMC article.
The NID uses statistics of lossless compression to compute a theoretically optimal metric distance between pairs of 5D movies, requiring no a priori knowledge of expected pattern dynamics, and no training data. ...The utility of a metric embedding follows from Euclidean di …
The NID uses statistics of lossless compression to compute a theoretically optimal metric distance between pairs of 5D movies, requir …
Health-related quality of life in patients with atrial fibrillation: The role of symptoms, comorbidities, and the type of atrial fibrillation.
Witassek F, Springer A, Adam L, Aeschbacher S, Beer JH, Blum S, Bonati LH, Conen D, Kobza R, Kühne M, Moschovitis G, Osswald S, Rodondi N, Sticherling C, Szucs T, Schwenkglenks M; Swiss-AF study investigators. Witassek F, et al. PLoS One. 2019 Dec 23;14(12):e0226730. doi: 10.1371/journal.pone.0226730. eCollection 2019. PLoS One. 2019. PMID: 31869399 Free PMC article.
Patients were included in this analysis if they had baseline HRQoL data as assessed with EQ-5D-based utilities and visual analogue scale (VAS) scores. Patient characteristics and HRQoL were described stratified by AF type. ...
Patients were included in this analysis if they had baseline HRQoL data as assessed with EQ-5D-based utilities and visual analogue sc …
Exposure to Ambient Particulate Matter during Specific Gestational Periods Produces Adverse Obstetric Consequences in Mice.
Blum JL, Chen LC, Zelikoff JT. Blum JL, et al. Environ Health Perspect. 2017 Jul 27;125(7):077020. doi: 10.1289/EHP1029. Environ Health Perspect. 2017. PMID: 28893721 Free PMC article.
FA) by 0.4d when exposure occurred during gestational periods 2 and 4, and by 0.5d if exposure occurred during period 3. Exposure during periods 1, 2, and 4 reduced birth weight by 10% compared with FA, and placental weight was reduced ( 8%) on GD17.5 if exposure occurr …
FA) by 0.4d when exposure occurred during gestational periods 2 and 4, and by 0.5d if exposure occurred during period 3. Exposure d …
Revisiting the OGIPRO Trial: Dynamic Electronic Patient-Reported Outcomes Compared with EQ-5D-5L in HER2-Positive Breast Cancer.
Aicher A, Vetter M, Blum D, Trojan A. Aicher A, et al. Cancers (Basel). 2026 Feb 13;18(4):614. doi: 10.3390/cancers18040614. Cancers (Basel). 2026. PMID: 41749867 Free PMC article.
In the prospective OGIPRO trial (KEK-ZH 2021-D0051), patients with HER2-positive breast cancer reported well-being and symptoms via the Medidux ePRO platform alongside weekly EQ-5D-5L assessments. In this retrospective analysis, we used linear mixed-effects modeling to exa …
In the prospective OGIPRO trial (KEK-ZH 2021-D0051), patients with HER2-positive breast cancer reported well-being and symptoms via the Medi …
20 results